Clinical Trials
28 trialsSELECT-CAR-NK
Essen Biotech
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
National Institutes of Health Clinical Center (CC)
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
Vall d'Hebron Institute of Oncology
ABILITY-1
Medicenna Therapeutics, Inc.
Efficacy of Interleukin-2 in Triple Negative Breast Cancer
Nova Scotia Health Authority
BAH249
Essen Biotech
Vaccine Therapy in Treating Patients With Metastatic Cancer
National Cancer Institute (NCI)
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
Second Affiliated Hospital of Soochow University
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
PACT Pharma, Inc.
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Institutes of Health Clinical Center (CC)
Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca
Masonic Cancer Center, University of Minnesota
Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer
Masonic Cancer Center, University of Minnesota
MT2009-30
Masonic Cancer Center, University of Minnesota
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
Fred Hutchinson Cancer Center
Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Roger Williams Medical Center
Biological Therapy in Treating Women With Stage IV Breast Cancer
Barbara Ann Karmanos Cancer Institute
A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors
Sun Yat-sen University
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Dendritic Cell Based Therapy for Breast Cancer Patients
Herlev Hospital
Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy
National Institutes of Health Clinical Center (CC)